Ultragenyx Announces Collaboration with Kyowa Hakko Kirin to Develop and Commercialize Phase 2-stage KRN23 for X-linked Hypophosphatemia
Exclusive partnership will advance global clinical development of
KRN23, an antibody for a rare bone disease
Novato, CA – September 3, 2013–Ultragenyx Pharmaceutical Inc.today announced it has entered into a collaboration and license agreement with Kyowa Hakko Kirin Co., Ltd. (KHK),to develop and commercialize KRN23. KRN23 is a recombinant fully human monoclonal IgG1 antibody intended to treat X-linked hypophosphatemia (XLH). KHK is currently completing a Phase 1/2 study in adults with XLH in the US and Canada. The two companies plan to initiate a pediatric XLH program in 2014.
© 2021 Pappas Capital, LLC. ALL RIGHTS RESERVED.